| Literature DB >> 34959277 |
Raphaëlle Youf1, Max Müller2, Ali Balasini3, Franck Thétiot4, Mareike Müller2, Alizé Hascoët1, Ulrich Jonas3, Holger Schönherr2, Gilles Lemercier5, Tristan Montier1,6, Tony Le Gall1.
Abstract
Antimicrobial photodynamic therapy (aPDT) has become a fundamental tool in modern therapeutics, notably due to the expanding versatility of photosensitizers (PSs) and the numerous possibilities to combine aPDT with other antimicrobial treatments to combat localized infections. After revisiting the basic principles of aPDT, this review first highlights the current state of the art of curative or preventive aPDT applications with relevant clinical trials. In addition, the most recent developments in photochemistry and photophysics as well as advanced carrier systems in the context of aPDT are provided, with a focus on the latest generations of efficient and versatile PSs and the progress towards hybrid-multicomponent systems. In particular, deeper insight into combinatory aPDT approaches is afforded, involving non-radiative or other light-based modalities. Selected aPDT perspectives are outlined, pointing out new strategies to target and treat microorganisms. Finally, the review works out the evolution of the conceptually simple PDT methodology towards a much more sophisticated, integrated, and innovative technology as an important element of potent antimicrobial strategies.Entities:
Keywords: ROS; antimicrobials; combinatory strategies; multidrug resistance; nanoparticles; photodynamic therapy; photosensitizers
Year: 2021 PMID: 34959277 PMCID: PMC8705969 DOI: 10.3390/pharmaceutics13121995
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1(A) Modified Jablonski diagram describing the photochemical and photophysical mechanisms leading to ROS production during PDT. (B) Overview of aPDT already applied to the critical category of pathogens, as defined by the NIAID (https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens, accessed date: 1 September 2021). For each category, the chart specifies the number and the proportion (percent of pathogens already assayed in at least one aPDT study either before or after 2015).
List of some recently completed or terminated clinical trials that evaluated aPDT to treat diverse infectious diseases.
| Medical Conditions | Target Micro-Organism(s) | Photosensitizer | Trial Phase | Number and Year |
|---|---|---|---|---|
|
|
| Butenyl ALA | N.A. | NCT02313467, 2014 |
| Lemuteporfin | Phase 1/2 | NCT01490736, 2011 | ||
| 5-ALA | Phase 2 | NCT01689935, 2012 | ||
| Methyl aminolevulinate | Phase 2 | NCT00673933, 2013 | ||
|
|
| TBO | Phase 1 | NCT02479958, 2015 |
| MB | Phase 1 | NCT02479958, 2015 | ||
|
| N.C. | N.A. | NCT03309748, 2017 | |
|
|
| MB | Phase 4 | NCT02642900, 2015 |
|
| N.D. | Curcumin | Phase 1 | NCT02337192, 2015 |
|
| N.D. | N.D. | Phase 3 | NCT02848482, 2016 |
|
|
| MB | N.A. | NCT03750162, 2018 |
| ICG | Phase 2 | NCT02043340, 2014 | ||
| Methyl aminolevulinate | Phase 2 | NCT00933543, 2013 | ||
| MB | N.A. | NCT03262077, 2017 | ||
| MB | Phase 2 | NCT03074136, 2017 | ||
| Phenothiazine hydrochloride | Phase 4 | NCT03498404, 2018 | ||
| TB | Phase 4 | NCT03412331, 2018 | ||
|
| Fungi infecting nails | 5-ALA | Phase 2 | NCT02355899, 2015 |
|
|
| MB | Phase 2 | NCT02824601, 2016 |
|
|
| 5-ALA | Phase 2 | NCT02631863, 2015 |
|
| Streptococci, anaerobes, coliform, | PPA904 | Phase 2 | NCT00825760, 2009 |
Studies collected from ClinicalTrials.gov (https://clinicaltrials.gov/ct2/results?cond=photodynamic+therapy, Accessed Date: 1 March 2021). ALA, alanine; MB, methylene blue; N.A., not applicable; N.C., not communicated; N.D., not determined; PPA904, 3,7-bis(di-n-butylamino)phenothiazin-5-ium bromide; and TB (or TBO), toluidine blue.
Figure 2Representative compounds in various classes of PSs used in aPDT. (A) Examples of some organic PSs and their derivatives. (B) Examples of metallic-based PSs. (C) Different types of polymer-based PS carriers, which can be functionalized with ligands for specific target delivery (Adapted from [94], published by MDPI, 2020).
Examples of recent studies that combined aPDT with other antimicrobial actives or treatments.
|
|
|
|
|
| 5-ALA + Gentamicin | In vitro: antibiofilm synergistic effect | [ | |
| Photodithazine + Metronidazole | In vitro: improvement of antibiofilm effect | [ | |
| Ce6 NP + Tinidazole | Periodontal pathogenic bacteria | In vitro: synergistic antiperiodontitis effects; in vivo: reduced adsorption of alveolar bone in a rat model of periodontitis | [ |
| MB + Clindamycin/Amoxicillin |
| In vitro: enhancement of antibiotic susceptibility following aPDT treatment; in vivo: prolonged survival of infected | [ |
| MB + Gentamicin | In vitro: synergistic effect on planctonik cultures of both bacteria; positive effect on | [ | |
| MB + Carbapenem | In vitro: impairment of the enzymatic activity and genetic determinants of carbapenemases; restoration of the susceptibility to Carbapenem | [ | |
| [Ir(ppy)2 |
| In vitro: synergistic aPDI effect with Cefotaxime | [ |
|
|
|
|
|
| MB or Ce6 + aurein 1.2 monomer or aurein 1.2 C-terminal dimer |
| In vitro: prevention of biofilm formation with all treatments; improvement of aurein monomer effect when combined with Ce6-PDT | [ |
| RB + Concanavalin A |
| In vitro: improvement of RB uptake, increased membrane damages and enhanced PDT effect | [ |
| MB@GNPDEX-ConA + Carbonyl cyanide m-chlorophenylhydrazone |
| In vitro: enhancement of the MB-NPs mediated phototoxicity with the efflux pump inhibitor CCCP | [ |
| Quinine hydrochloride + antimicrobial blue light | MDR | In vitro: photo-inactivation of planktonic cells and biofilms; in vivo: potentiation of aBL effect in a mouse skin abrasion infection model | [ |
|
|
|
|
|
| 5-ALA + ITZ, itraconazole; TBF, terbinafine; VOR, voriconazole | In vitro: reduction/improvement of lesions, disappearance of plaque | [ | |
| Photodithazine + Nystatin | Fluconazole-resistant | In vitro: reduction of fungal viability, decrease in oral lesions and inflammatory reaction; in vivo: decrease in tongue lesions | [ |
| 5-ALA + Itraconazole |
| In vitro: better elimination of planktonic and biofilms fungi than single therapy | [ |
|
|
|
|
|
| Schiff base complexes |
| In vitro: blockage of the production of inflammatory TNFα cytokine | [ |
| Porphyrin + phtalocyanine | HIV-infected cells | In vitro: specific phototoxicity against infected cells | [ |
|
|
|
|
|
| Ce6 derivative Photodithazine + RB |
| In vitro: inactivation of biofilm (viability and total biomass) | [ |
| UCNPs + hematoporphyrin + SiO2-RB 1 | Antibiotic-resistant bacteria | In vitro: greater antibacterial effect with SDT and PDT at once | [ |
|
|
|
|
|
| Hypericin | In vitro: better bacterial inactivation with combined therapies | [ | |
|
|
|
|
|
| TVP-A (luminogen) + PAP phage |
| In vitro: synergistic bacterial recognizing and killing; in vivo: acceleration of healing rates | [ |
| Pheophorbide A (chlorophyll) + JM-phage |
| In vitro: better specificity of PS targeting | [ |
| Ru(bpy2)phen-IA + Cowpea chlorotic mottle virus |
| In vitro: targeted bacterial photodynamic inactivation | [ |
|
|
|
|
|
| Carboxypterin + MB |
| In vitro: better biofilm eradication | [ |
| Phthalocyanines + Graphene QDs |
| In vitro: better bacterial photoinactivation | [ |
| ICG + Metformin + Curcumin |
| In vitro: better biofilm eradication | [ |
| Porphyrin + Phthalocyanine |
| In vitro: better assimilation of photo-inactivated parasites by macrophages | [ |
|
|
|
|
|
| Ruthenium NPs | Pathogenic bacteria | In vitro: bacterial inhibition; in vivo: reduction of bacterial load and repair of infected wounds | [ |
| Graphene oxide | In vitro: efficient vector for both PDT and PTT | [ | |
| ICG + SPIONs | In vitro: antimicrobial and antibiofilm activity at a low dose | [ | |
| Ag-conjugated graphene QDs | In vitro: efficient photoinactivation by PDT and PTT; in vivo: promoted healing in bacteria-infected rat wounds | [ | |
| PDPPTT (photothermal agent) + MEH-PPV (PS) 2 |
| In vitro: better inhibition rate than PTT/PDT systems used alone | [ |
| Mesoporous polydopamine NPs + ICG |
| In vivo: eradication of | [ |
|
|
|
|
|
| N-(3-aminopropyl)-3-(trifluoromethyl)-4-nitrobenzenamine + TMPyP/ZnPc |
| In vitro: dual-mode photoantibacterial action | [ |
| Sulfonated polystyrene NPs (NO photodonor + porphyrin/phthalocyanine) |
| In vitro: strong antibacterial action | [ |
| [Ru(bpy)3]Cl2 |
| In vitro: PDT/NO synergistic antibiofilm effect | [ |
ALA, alanine; MB, methylene blue; RB, rose bengal; Ce6, chlorin e6; ICG, indocyanine green; SPION, superparamagnetic iron oxide NP. 1, hematoporphyrin monomethyl ether enclosed into yolk-structured up-conversion core and covalently linked RB on SiO2 shell; 2, photothermal agent poly(diketopyrrolopyrrole-thienothiophene) (PDPPTT) and the photosensitizer poly(2-methoxy-5-((2-ethylhexyl)oxy)-p-phenylenevinylene) (MEH-PPV) in the presence of poly(styrene-co-maleic anhydride).